FDA-cleared profile

Bunkerhill AVC

BunkerHill Health · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Adjunctive opportunistic detection and quantification of aortic valve calcification during routine clinical-care chest CT review; a physician reviews the informational ROI and estimated calcium burden and decides any further action.

Clinical role
Adjunctive, on-demand informational support for physician review; the output is not a stand-alone diagnostic decision and does not replace the original report or CT study.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The cleared population is adults aged 40 years and above with non-gated, non-contrast chest CT. The ROI and score are informational, results are not intended for stand-alone use, and physician review of the original report and CT remains required; performance outside the submitted study conditions was not established here.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive opportunistic detection and quantification of aortic valve calcification during routine clinical-care chest CT review; a physician reviews the informational ROI and estimated calcium burden and decides any further action.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Adult non-gated, non-contrast chest CT images, received in DICOM format from compatible CT systems; the FDA comparison lists slice thickness up to 5 mm.
  • Who uses it?Intended users: Qualified medical professionals such as cardiologists or radiologists.
  • What does the software produce?Output: An informational circular ROI localizing detected aortic-valve calcium and an estimated Agatston-equivalent calcium score; the quantification can be viewed in the patient report and the ROI in a diagnostic image viewer.
  • What is its most important limitation?Key limitation: The cleared population is adults aged 40 years and above with non-gated, non-contrast chest CT. The ROI and score are informational, results are not intended for stand-alone use, and physician review of the original report and CT remains required; performance outside the submitted study conditions was not established here.

Clinical takeaway. Clinical role: Adjunctive opportunistic detection and quantification of aortic valve calcification during routine clinical-care chest CT review; a physician reviews the informational ROI and estimated calcium burden and decides any further action.

Evidence takeaway. Evidence from the reviewed source record: The FDA-described retrospective stand-alone validation used cases from 33 sites across three US geographic regions. Reported agreement bias was -5.15 AU with lower and upper limits of agreement of -200.96 AU and 190.65 AU; circular-ROI precision was 0.826 and recall was 0.855.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive opportunistic detection and quantification of aortic valve calcification during routine clinical-care chest CT review; a physician reviews the informational ROI and estimated calcium burden and decides any further action.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Adjunctive, on-demand informational support for physician review; the output is not a stand-alone diagnostic decision and does not replace the original report or CT study.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Adult non-gated, non-contrast chest CT images, received in DICOM format from compatible CT systems; the FDA comparison lists slice thickness up to 5 mm.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
An informational circular ROI localizing detected aortic-valve calcium and an estimated Agatston-equivalent calcium score; the quantification can be viewed in the patient report and the ROI in a diagnostic image viewer.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Medical facilities providing routine clinical-care chest CT and physician interpretation.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Qualified medical professionals such as cardiologists or radiologists.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The cleared population is adults aged 40 years and above with non-gated, non-contrast chest CT. The ROI and score are informational, results are not intended for stand-alone use, and physician review of the original report and CT remains required; performance outside the submitted study conditions was not established here.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
The FDA-described retrospective stand-alone validation used cases from 33 sites across three US geographic regions. Reported agreement bias was -5.15 AU with lower and upper limits of agreement of -200.96 AU and 190.65 AU; circular-ROI precision was 0.826 and recall was 0.855.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA-described retrospective stand-alone validation used cases from 33 sites across three US geographic regions. Reported agreement bias was -5.15 AU with lower and upper limits of agreement of -200.96 AU and 190.65 AU; circular-ROI precision was 0.826 and recall was 0.855.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The FDA summary reports ROI precision and recall plus agreement endpoints, not a disease-detection sensitivity measure.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The FDA summary reports ROI precision and recall plus agreement endpoints, not a disease-detection specificity measure.

Bland-Altman mean bias

-5.15 Agatston-equivalent units (AU)

  • EndpointMean difference between estimated aortic-valve calcium burden and ground truth
  • PopulationRetrospective stand-alone validation cases from 33 sites across three US geographic regions
  • Tested versionBunkerhill AVC configuration submitted in K243229

Bland-Altman lower limit of agreement

-200.96 Agatston-equivalent units (AU)

  • EndpointLower limit of agreement for estimated aortic-valve calcium burden
  • PopulationRetrospective stand-alone validation cases from 33 sites across three US geographic regions
  • Tested versionBunkerhill AVC configuration submitted in K243229

Bland-Altman upper limit of agreement

190.65 Agatston-equivalent units (AU)

  • EndpointUpper limit of agreement for estimated aortic-valve calcium burden
  • PopulationRetrospective stand-alone validation cases from 33 sites across three US geographic regions
  • Tested versionBunkerhill AVC configuration submitted in K243229

Circular ROI precision

0.826 proportion

  • EndpointPrecision of detected aortic-valve calcium ROI
  • PopulationRetrospective stand-alone validation cases from 33 sites across three US geographic regions
  • Tested versionBunkerhill AVC configuration submitted in K243229

Circular ROI recall

0.855 proportion

  • EndpointRecall of detected aortic-valve calcium ROI
  • PopulationRetrospective stand-alone validation cases from 33 sites across three US geographic regions
  • Tested versionBunkerhill AVC configuration submitted in K243229

Bunkerhill AVC pivotal stand-alone validation

  • DesignRetrospective stand-alone validation with Bland-Altman agreement as the primary endpoint and circular-ROI precision and recall as secondary endpoints.
  • PopulationCases curated from 33 sites across three geographic regions in the United States; the reviewed FDA summary does not state the total number of cases.
  • Scopeexact submission
  • Tested versionBunkerhill AVC configuration submitted in K243229
  • Sites33
  • IndependenceSponsor or vendor study

K243229

This is an FDA submission validation study of localization and agreement against established ground truth, not an independent clinical-outcomes study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-submission FDA recall query returned no native recall record for K243229. This limited result does not establish absence of recall or other safety information and does not cover later versions, family records, or adverse-event sources.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07

The local exact-ID recall packet contained zero records; this is a limited query result, not a safety clearance.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult non-gated, non-contrast chest CT images, received in DICOM format from compatible CT systems; the FDA comparison lists slice thickness up to 5 mm.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K243229: Bunkerhill AVC

  2. Routing

    Source context, not route validation: The SaMD interfaces with compatible commercially available CT systems and receives DICOM CT images; the result can be shown as a separate ROI series in a diagnostic viewer or as an estimated score in the patient report while the original study remains available.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K243229: Bunkerhill AVC

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed exact FDA summary and vendor announcement establish the CT/DICOM workflow but do not establish whether the current exact configuration is cloud, on-premises or hybrid.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 ·

  4. Returned objects

    Source context, not route validation: An informational circular ROI localizing detected aortic-valve calcium and an estimated Agatston-equivalent calcium score; the quantification can be viewed in the patient report and the ROI in a diagnostic image viewer.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K243229: Bunkerhill AVC

  5. Viewer/worklist/report

    Unresolved route: An informational circular ROI localizing detected aortic-valve calcium and an estimated Agatston-equivalent calcium score; the quantification can be viewed in the patient report and the ROI in a diagnostic image viewer.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K243229: Bunkerhill AVC

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The SaMD interfaces with compatible commercially available CT systems and receives DICOM CT images; the result can be shown as a separate ROI series in a diagnostic viewer or as an estimated score in the patient report while the original study remains available.
  • Exact FDA submission
  • Checked 2026-09-07
Security
Bunkerhill Health's website states SOC 2 Type II certification, HIPAA compliance and ISO/IEC 27001:2022 certification. Badges only: no scope, dates or controls are given. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

DICOM and physician-review outputs

The cleared workflow accepts non-gated, non-contrast chest CT in DICOM and makes an informational ROI available in a diagnostic viewer plus an estimated calcium score available in the patient report.

exact submission · checked 2026-09-07

Opportunistic aortic-valve calcification workflow

Bunkerhill describes AVC as an AI solution that detects and quantifies aortic valve calcification on non-gated, non-contrast chest CT and offers a health-system demo/contact path.

product family · checked 2026-09-08

Vendor announcement content is current buyer context; exact K243229 installation, hosting, security, price and support terms remain unestablished.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243229
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-01-27
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
20Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is metadata screening, not a full-paper or systematic literature review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor announcement, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K243229 configuration was reviewed.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established. A general database search cannot prove coverage or noncoverage; verify payer, site of service, coding, and local payment assumptions.

  • Deployment: Not publicly available - checked 2026-09-07 - Exact FDA submission

    The reviewed exact FDA summary and vendor announcement establish the CT/DICOM workflow but do not establish whether the current exact configuration is cloud, on-premises or hybrid.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA 510(k) K243229: Bunkerhill AVC

    U.S. Food and Drug Administration - Published 2025-01-27 - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Bunkerhill AVC model card (K243229)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Bunkerhill Health secures FDA clearance for Bunkerhill AVC

    Bunkerhill Health - Published 2025-01-29 - Accessed 2026-09-08

    Scope: productFamily, clinicalWorkflow

  8. openFDA exact recall query for K243229

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

  9. Bunkerhill Health home page security claims

    Bunkerhill Health - Accessed 2026-10-25

    Scope: security

Research history

  1. K243229 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K183012

vascuCAP

Elucid Bioimaging Inc.

Authorized purpose: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2018-12-21
FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history